Guangdong Xipeng Tuling Biotechnology Co., Ltd.

Primary objectives: 1) To evaluate the safety of CN-105 peptide for injection in the treatment of patients with acute ischemic stroke (AIS). Secondary objectives: 1) To evaluate the effectiveness of CN-105 peptide for injection in the treatment of patients with acute ischemic stroke (AIS). Exploratory objectives: 1) To explore the correlation between protein markers (cytokines and chemokines and nervous system-related molecules) and the efficacy of CN-105 peptide for injection; 2) To explore the correlation between single nucleotide polymorphisms (SNPs) and APOE gene subtypes in the TOMM40-APOE locus and the efficacy of CN-105 peptide for injection.

Primary objective: To evaluate the safety and tolerability of different doses of CN-105 peptide for injection in patients with acute supratentorial intracerebral hemorrhage. Secondary objective: To evaluate the effectiveness of different doses of CN-105 peptide for injection in patients with acute supratentorial intracerebral hemorrhage. Exploratory objective: To explore the effects of different doses of CN-105 peptide for injection on the edema around the hematoma and the condition of the injured lesions; to explore the correlation between protein markers (cytokines and chemokines and nervous system-related molecules) and the efficacy of CN-105; to explore the correlation between single nucleotide polymorphisms (SNPs) in the TOMM40-APOE locus and APOE gene subtypes and the efficacy of CN-105.

Primary objective: To evaluate the safety and tolerability of single and four-times-daily, 13-times-consecutive intravenous infusions of different doses of CN-105. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of single and four-times-daily, 13-times-consecutive intravenous infusions of different doses of CN-105.